Skip to content

US · EMBC · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Embecta Corp. (EMBC) intrinsic value and stock valuation

$6.02as of 2026-11-21 · Mkt cap 262.23M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Embecta Corp. DCF and intrinsic value

InvestorsCraft values EMBC with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from EMBC’s statements →

Embecta Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Parsippany, NJ 07054 embecta.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$1.08B-0.1% 5y CAGRd
20192025
Net income
$95.4M-25.9% 5y CAGRd
20192025
Free cash flow
$182.4M-16.8% 5y CAGRd
20192025
Total equity
-$-651.2M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$1.08B$1.12B$1.12B$1.13B$1.17B
Operating income$329.3M$174.2M$229.6M$378.1M$492M
Net income$95.4M$78.3M$70.4M$223.6M$414.8M
EPSd$1.62M$1.34M$1.22M$3.92M$7.3M
Operating cash flow$191.7M$35.7M$67.7M$412.2M$456M
Capital expenditure-$-9.3M-$-15.8M-$-26.5M-$-24M-$-39M
Free cash flow$182.4M$19.9M$41.2M$388.2M$417M
Total assets$1.09B$1.29B$1.21B$1.09B$788M
Total debt$1.43B$1.61B$1.64B$1.64B$4.1M
Net debt$1.2B$1.34B$1.31B$1.31B$4.1M
Total equity-$-651.2M-$-738.3M-$-821.7M-$-891.4M$594M
Cash and short-term investments$225.5M$267.5M$326.5M$330.9M$0.00
Income statement
20252024202320222021
Revenue$1.08B$1.12B$1.12B$1.13B$1.17B
Cost of revenue$400.9M$394.2M$370.9M$354.6M$365M
Gross profit$679.5M$728.9M$749.9M$774.9M$800M
Research and development expenses$21.5M$78.8M$85.2M$65M$63M
Selling, general and administrative expenses$331.4M$365.1M$341.3M$294.8M$240.3M
Other expenses-$-2.7M$110.8M$93.8M$37M$5M
Operating expenses$350.2M$554.7M$520.3M$396.8M$308M
Cost and expenses$751.1M$948.9M$891.2M$751.4M$673M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$107.3M$112.3M$107M$46.2M$0.00
Depreciation and amortization$51.1M$42.5M$32.7M$31.7M$38M
Ebitda$294.7M$199M$245.4M$334.5M$533M
Operating income$329.3M$174.2M$229.6M$378.1M$492M
Total other income/expenses, net-$-193M-$-130M-$-123.9M-$-121.5M$3M
Income before tax$136.3M$44.2M$105.7M$256.6M$495M
Income tax expense$40.9M-$-34.1M$35.3M$33M$80M
Net income$95.4M$78.3M$70.4M$223.6M$414.8M
Weighted average shares outstanding$58.3M$58.4M$57.2M$57.1M$56.8M
Weighted average diluted shares outstanding$58.9M$58.3M$57.8M$57.1M$56.8M
Balance sheet
20252024202320222021
Cash and short-term investments$225.5M$267.5M$326.5M$330.9M$0.00
Net receivables$148.9M$248M$17.9M$23.4M$150.6M
Inventory$178.6M$171.5M$152.1M$122.8M$118M
Total current assets$631.4M$761M$749.1M$664.7M$292M
Property, plant and equipment, net$257.2M$290.4M$323.2M$301.6M$451M
Goodwill and intangible assets$22.4M$23.7M$24.7M$24.6M$34M
Long-term investments$0.00$0.00$0.00-$-95.5M-$-11.4M
Total non-current assets$459.5M$524.3M$465.3M$421.7M$496M
Total assets$1.09B$1.29B$1.21B$1.09B$788M
Accounts payable$74.2M$91M$53.5M$41.4M$54.2M
Short-term debt$12.9M$12.9M$19M$13.1M$2.1M
Deferred revenue$0.00$0.00$33.6M$0.00$0.00
Total current liabilities$261.5M$374M$353.5M$301M$164M
Long-term debt$1.42B$1.6B$1.63B$1.64B$3M
Deferred revenue, non-current$0.00$0.00$0.00-$-46.1M$0.00
Total non-current liabilities$1.48B$1.65B$1.68B$1.68B$29.7M
Capital lease obligations$32.1M$33.6M$41M$40.5M$4.1M
Total liabilities$1.74B$2.02B$2.04B$1.98B$194M
Common stock$0.00$600K$600K$600K$865M
Retained earnings-$-445.6M-$-498.6M-$-541.1M-$-577.1M$0.00
Accumulated other comprehensive income (loss)-$-285.6M-$-292.8M-$-309.1M-$-324.9M-$-271M
Total equity-$-651.2M-$-738.3M-$-821.7M-$-891.4M$594M
Total investments$0.00$0.00$0.00-$-95.5M-$-11.4M
Total debt$1.43B$1.61B$1.64B$1.64B$4.1M
Net debt$1.2B$1.34B$1.31B$1.31B$4.1M
Cash flow statement
20252024202320222021
Net income$95.4M$78.3M$70.4M$223.6M$415M
Depreciation and amortization$40.7M$36.2M$32.6M$31.7M$38M
Stock-based compensation$31.6M$26.3M$21.5M$18.7M$12.8M
Change in working capital-$-23.7M-$-47.7M-$-80M$92.4M-$-32M
Accounts receivable$44.2M-$-174.7M$7M$122.7M-$-32M
Inventory-$-6.1M-$-16.5M-$-28.8M-$-23.4M-$-18M
Accounts payable-$-68.9M$60M$7.9M$73.3M$30M
Net cash provided by operating activities$191.7M$35.7M$67.7M$412.2M$456M
Investments in property, plant and equipment-$-9.3M-$-15.8M-$-26.5M-$-24M-$-39M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-9.3M-$-15.8M-$-26.5M-$-24M-$-39M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-5.7M-$-3M-$-3.6M$0.00$0.00
Dividends paid-$-35M-$-34.5M-$-34.4M-$-8.6M$0.00
Net cash used for financing activities-$-226.7M-$-73.4M-$-48.7M-$-48M-$-417M
Net change in cash-$-45.6M-$-52.3M-$-4.4M$330.9M$0.00
Cash at end of period$228.6M$274.2M$326.5M$330.9M$0.00
Operating cash flow$191.7M$35.7M$67.7M$412.2M$456M
Capital expenditure-$-9.3M-$-15.8M-$-26.5M-$-24M-$-39M
Free cash flow$182.4M$19.9M$41.2M$388.2M$417M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Embecta Corp.

        Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

        CEO
        Devdatt Kurdikar
        Employees
        1.85K
        Beta
        0.81

        Explore

        Frequently asked questions

        What is the intrinsic value of Embecta Corp. (EMBC)?

        Embecta Corp. (EMBC) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is EMBC undervalued?

        EMBC trades at a price of $6.02 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.